Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

. 2006 Nov 22;81(3):1424–1432. doi: 10.1128/JVI.02054-06

TABLE 2.

Neutralization endpoints for 2909 against Envs with variant sequences in the V1/V2 domain

Clade B consensusb V2 sequence at positiona IC50 (μg/ml) IC90 (μg/ml)
160167
GEIKNCSFNITTSIRDKVQKEYALFY
SF162 --------KV-----N-M-------- 0.00019 1.1
    SF-NI (K160N/V161I) ---------------N-M-------- >20 >20
    SF-GKV (N167G/M169V) --------KV-----G---------- 1.3 >20
    SF-NKV (M169V) --------KV-----N---------- 0.0088 5.5
    SF-DKV (N167D/M169V) --------KV---------------- 0.000078 0.010
    SF-DKM (N167D) --------KV-------M-------- 0.000080 0.0031
JR-FL ----------------E--------- >100 >100
    JR-FL (N160K) --------K-------E--------- 25 >100
    JR-FL (E168K) -------------------------- >20 >20
    JR-FL (N160S/E168K) --------S----------------- 0.70 6.3
    JR-FL (N160K/E168K) --------K----------------- 0.00034 0.0093
    SF162 (JR-FL V1V2 N160K/E168K) --------K----------------- 0.00012 0.0030
YU2 -------------------------- >20 >20
    YU2 (N160K) --------K----------------- 0.079 6.8
    YU2 (T133A/N160K)c --------K----------------- 0.0053 2.9
a

V2 residues 152-177 (based on the HXB2 numbering system) are compared to the clade B consensus sequence. Dashes indicate residues identical to those of the consensus sequence. N-linked glycosylation signals [NX(S/T)] are underlined.

b

Env variants are described by listing in parentheses the original residue, the position, and the modified residue. For SF162 variants, a shorter name corresponding to that used in Fig. 1 is also provided in which the residues at key positions 160 to 161 or 167 to 169 are indicated. IC50 and IC90 values are averages of at least three independent assays.

c

See Table 3 for the YU2 V1 region sequence.

HHS Vulnerability Disclosure